Abstract
Background
At present, whether sitagliptin has sex-related differences in effect on atherosclerosis in type 2 diabetes mellitus (T2DM) patients is unknown. The purpose of this study was to investigate whether there is sex-related difference in the effect of sitagliptin on atherosclerosis in T2DM patients.
Material/Methods
In the PROLOGUE trial, 222 patients were allocated to the sitagliptin group and 220 patients were allocated to the conventional group. Carotid artery intima-media thickness (IMT) was assessed at baseline, 12 months, and 24 months.
Results
In male patients, sitagliptin significantly reduced the mean IMT (0.84±0.41 mm vs 1.02±0.67 mm, P=0.013) and the maximum IMT (1.14±0.59 mm vs 1.39±0.88 mm, P=0.016) in the right internal carotid arteries (ICA) compared to the conventional group at 12 months. Similarly, sitagliptin significantly reduced the maximum IMT (1.09±0.52 mm vs 1.28±0.77 mm, P=0.049) in the right ICA compared to the conventional group at 24 months, but no difference was found in the mean IMT in the right ICA between groups at 24 months. In female patients, sitagliptin significantly reduced the mean IMT (1.01±0.47 mm vs 1.23±0.51 mm, P=0.049) and the maximum IMT (1.39±0.65 mm vs 1.71±0.77 mm, P=0.042) in the right bulb compared to the conventional group at 12 months. However, the group differences were not observed in mean IMT and maximum IMT at 24 months.
Conclusions
Our results suggest that sitagliptin slows the progression of right carotid IMT in male patients. However, more research is needed to validate this finding in female patients.
Keywords: 1,5,5-Triallylbarbituric Acid; 46, XY Sex Reversal 5; 6q24-Related Transient Neonatal Diabetes Mellitus; Sitagliptin Phosphate
Background
Atherosclerosis [1–3] is a chronic non-infectious inflammation of the arterial wall. Previous studies have shown that cardiovascular [4,5] and cerebrovascular [6,7] diseases caused by atherosclerosis are some of the leading causes of death in developed and developing countries. In China, atherosclerosis has become one of the main causes of death [8,9]. Atherosclerosis is caused by a variety of factors, including endothelial cell injury, dyslipidemia, diabetes, hypertension, and chronic inflammation. Among these factors, type 2 diabetes mellitus (T2DM) is a critical risk factor for atherosclerosis [10–12]. There is clinical evidence showing higher risk of coronary heart disease (CHD) [13] and ischemic stroke (IS) [14] in T2DM patients than in patients with a single disease. Therefore, the main focus of research has been to determine ways to delay or reduce the degree of atherosclerosis in T2DM patients.
Dipeptidyl peptidase-4 (DPP-4) inhibitor [15,16] is a new therapeutic drug for the treatment of diabetes. It can elevate the activity of endogenous glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), promote the release of insulin by islet B cells, and restrain the excretion of glucagon, thus causing an increase in insulin concentration and a drop in blood glucose. Sitagliptin, one of the inhibitors of DPP-4 inhibitors, has been widely assessed in previous studies [17,18]. However, whether sitagliptin can effectively delay the progression of atherosclerosis in T2DM patients and thus reduce cardiovascular events remains controversial. Some previous studies have found that sitagliptin does not improve the degree of atherosclerosis in T2DM patients [19,20], nor reduce the risk of cardiovascular events [21,22]. On the contrary, some other studies have supported the benefits of sitagliptin in T2DM patients [23–25]. It is likely that these conflicting results are due to sex-related differences, since males and females have different levels of hormone secretion (eg, androgens, estrogens, and progestins), which could potentially impact the effectiveness of sitagliptin treatment in T2DM patients. In addition, there have been no studies reporting sex-related differences in the effect of sitagliptin on carotid artery IMT. Therefore, the objective of our study was to re-analyze the PROLOGUE study, and explore whether sex-related differences impact the effectiveness of sitagliptin treatment in patients with T2DM [19].
Material and Methods
We obtained all data analyzed in this study from an open database (datadryad: https://datadryad.org/stash). Datadryad is a non-profit database that allows researchers to download the data for free, for the purpose of verifying the accuracy of the results or conducting different statistical analysis based on different research assumptions. For this study, we downloaded the data from the PROLOGUE trial [19] (Oyama, Jun-ichi et al (2017), Data from: The effect of sitagliptin on carotid artery atherosclerosis in Type 2 Diabetes: the PROLOGUE randomized controlled trial, Dryad, Dataset, https://doi.org/10.5061/dryad.qt743). The detailed results of the PROLOGUE study have been described in previous studies [19,25]. In brief, PROLOGUE is a multicenter, prospective, randomized clinical trial conducted in 48 institutions in Japan. The study recruited 463 T2DM patients treated in 48 institutions between June 2011 and September 2012 [19]. The participants were >30 years old, with glycated hemoglobin (HbA1c) ranging from 6.2% to 9.4%. Exclusion criteria were: patients with type 1 diabetes, patients with severe heart failure (NYHA ≥III grade), patients who had been treated with DPP-4 inhibitors and/or GLP-1 analogs, patients with severe renal insufficiency, pregnant patients, and patients without informed consent. Other details of inclusion and exclusion criteria have been described in previous studies [19,25]. Based on the inclusion and exclusion criteria, 442 participants were finally included in the study. The participants were randomly assigned to the sitagliptin group (n=222, 25–100 mg/d) or the conventional group (n=220) in a 1: 1 ratio. The sitagliptin group included 146 male participants and 76 female participants, while the conventional group include 151 male participants and 69 female participants. Since this study was a secondary analysis of a prior study, no informed consent of patients or approval certificate by an ethics committee was necessary.
Endpoints
The primary endpoint of our current study included changes in the mean IMT in the right and the left common carotid arteries (CCA), the mean IMT in the right and the left bulb, the mean IMT in the right and the left internal carotid arteries (ICA), the maximum IMT in the right and the left CCA, the maximum IMT in the right and the left bulb, and the maximum IMT in the right and the left ICA. The primary endpoints were measured by high-resolution carotid ultrasonography at baseline, 12 months, and 24 months by expert sonographers trained in the measurement of carotid IMT, as described in Oyama et al [19]. In addition, all ultrasonic systems were equipped with more than 7.5 MHz linear sensors. The secondary endpoints included weight, waist circumference (WC), systolic blood pressure (SDP), diastolic blood pressure (DBP), pulse rate (PR), HbA1c, fasting plasma glucose (FPG), 1,5-anhydroglucitol,1,4-anhydro-D-glucitol, high-molecular-weight adiponectin (HMWA), lactic dehydrogenase (LD), high-density lipoprotein cholesterol (HDL-cholesterol), triglyceride (TG), small dense low-density lipoprotein cholesterol (small DLD-cholesterol), remnant-like particle cholesterol (RLP-cholesterol), malondialdehyde-modified low-density lipoprotein (MMDLI), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR), cystatin C, and urinary albumin/creatinine ratio, and were measured at 24 months.
Statistical Analysis
The Shapiro-Wilk test was used to judge the normality of continuous variables. In this study, we first divided all participants into 2 groups based on sex, and then explored the effect of sitagliptin on carotid atherosclerosis in T2DM patients. We used mean and standard deviations to represent normally distributed continuous variables, and used the independent-samples t test or repeated measures variance to compare differences between groups when appropriate. Continuous variables without normal distribution are presented as median (IQ) range, and the Mann-Whitney test or Kruskal Wallis test was used to compare differences between groups. We expressed categorical variables by numbers and percentages, and used the chi-square test to compare differences between groups. We used odds ratios (OR) with 95% confidence interval (CI) to express the difference between groups. P value <0.05 was considered statistically significant (2-sided) difference. We used SPSS 24.0 statistical software and R software (version 3.6.2) for statistical analysis.
Results
Baseline Characteristics of Male Participants
Table 1 shows the baseline characteristics and baseline laboratory information for male participants. The average age of participants in the sitagliptin and the conventional group was 68.21±9.22 years and 68.66±9.24 years, respectively. No significant differences were observed in height, weight, SBP, DBP, HbA1c, FPG, serum creatinine, eGFR, mean IMT in the right and the left CCA, mean IMT in the right and the left bulb, mean IMT in the right and the left ICA, maximum IMT in the right and the left CCA, maximum IMT in the right and the left bulb, maximum IMT in the right and the left ICA, plaque area, plaque gray-scale median, and history of medication and diseases between the 2 groups (all P>0.05).
Table 1.
Baseline characteristics of male participants.
| Characteristic | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|
| N | 146 | 151 | |
| Age, years | 68.21±9.22 | 68.66±9.24 | 0.670 |
| Height, cm | 164.55±6.66 | 165.06±5.50 | 0.479 |
| Weight, kg | 68.89±10.69 | 68.04±10.82 | 0.498 |
| Body mass index, kg/m2 | 25.20±3.49 | 25.10±3.91 | 0.834 |
| Waist circumference, (cm) | 90.98±9.52 | 89.67±9.71 | 0.267 |
| Systolic blood pressure, mmHg | 130.01±16.22 | 127.77±15.83 | 0.231 |
| Diastolic blood pressure, mmHg | 73.66±10.34 | 72.62±11.33 | 0.409 |
| HbA1c,% | 6.54±0.52 | 6.57±0.52 | 0.593 |
| Fasting plasma glucose, mmol/l | 141.75±44.04 | 135.86±34.48 | 0.210 |
| Serum creatinine, μmol/l | 0.93±0.22 | 0.94±0.25 | 0.649 |
| Estimated glomerular filtration rate, ml/min/1.73 m2 | 66.43±16.47 | 65.91±16.65 | 0.786 |
| Hypertension, N (%) | 121 (82.88%) | 116 (76.82%) | 0.194 |
| Dyslipidemia, N (%) | 105 (71.92%) | 99 (65.56%) | 0.238 |
| Cerebral infarction, N (%) | 11 (7.53%) | 17 (11.26%) | 0.272 |
| Cerebral hemorrhage, N (%) | 2 (1.37%) | 1 (0.66%) | 0.542 |
| Myocardial infarction, N (%) | 39 (26.71%) | 49 (32.45%) | 0.279 |
| Arrhythmia, N (%) | 20 (13.70%) | 25 (16.56%) | 0.492 |
| Chronic heart failure, N (%) | 12 (8.22%) | 19 (12.58%) | 0.219 |
| Percutaneous coronary intervention, N (%) | 45 (30.82%) | 51 (33.77%) | 0.586 |
| Coronary artery bypass grafting, N (%) | 15 (10.27%) | 15 (9.93%) | 0.923 |
Baseline Characteristics of Female Participants
Table 2 shows the baseline characteristics and baseline laboratory information for female participants. The average age of participants in the sitagliptin group and the conventional group was 71.04±9.10 years and 71.35±8.83 years, respectively. Similar to male participants, no significant differences were observed in height, weight, SBP, DBP, HbA1c, FPG, serum creatinine, eGFR, mean IMT in the right and the left CCA, mean IMT in the right and the left bulb, mean IMT in the right and the left ICA, maximum IMT in the right and the left CCA, maximum IMT in the right and the left bulb, maximum IMT in the right and the left ICA, plaque area, plaque gray scale median, and history of medication and diseases between the 2 groups (all P>0.05).
Table 2.
Baseline characteristics of female participants.
| Characteristic | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|
| N | 76 | 69 | |
| Age, years | 71.04±9.10 | 71.35±8.83 | 0.837 |
| Height, cm | 151.23±5.29 | 150.00±5.70 | 0.180 |
| Weight, kg | 57.95±13.62 | 55.62±10.46 | 0.255 |
| Body mass index, kg/m2 | 25.15±5.03 | 24.82±4.68 | 0.688 |
| Waist circumference, (cm) | 86.97±11.68 | 86.10±11.97 | 0.876 |
| Systolic blood pressure, mmHg | 130.08±14.74 | 130.88±17.76 | 0.766 |
| Diastolic blood pressure, mmHg | 71.26±11.24 | 69.67±11.64 | 0.402 |
| HbA1c,% | 6.58±0.53 | 6.58±0.58 | 0.981 |
| Fasting plasma glucose, mmol/l | 131.49±35.92 | 133.21±41.93 | 0.796 |
| Serum creatinine, μmol/l | 0.71±0.18 | 0.69±0.19 | 0.588 |
| Estimated glomerular filtration rate, ml/min/1.73 m2 | 66.49±19.09 | 68.78±20.79 | 0.491 |
| Hypertension, N (%) | 60 (78.95%) | 50 (72.46%) | 0.362 |
| Dyslipidemia, N (%) | 58 (76.32%) | 49 (71.01%) | 0.468 |
| Cerebral infarction, N (%) | 10 (13.16%) | 8 (11.59%) | 0.776 |
| Cerebral hemorrhage, N (%) | 1 (1.32%) | 0 (0.00%) | 0.339 |
| Myocardial infarction, N (%) | 7 (9.21%) | 6 (8.70%) | 0.914 |
| Arrhythmia, N (%) | 12 (15.79%) | 7 (10.14%) | 0.314 |
| Chronic heart failure, N (%) | 3 (3.95%) | 7 (10.14%) | 0.141 |
| Percutaneous coronary intervention, N (%) | 13 (17.11%) | 18 (26.09%) | 0.188 |
| Coronary artery bypass grafting, N (%) | 4 (5.26%) | 1 (1.45%) | 0.209 |
Comparison of Atherosclerotic Parameters in Male Participants at 12 Months and 24 Months
Our results show that in male patients, sitagliptin significantly reduced mean IMT (0.84±0.41 mm vs 1.02±0.67 mm, group differences: −0.19, −0.34 to −0.04) (Figure 1A) and maximum IMT (1.14±0.59 mm vs 1.39±0.88 mm, group differences: −0.25, −0.45 to −0.05) in the right ICA (Figure 1B) compared to the conventional group at 12 months. Similarly, sitagliptin also significantly reduced maximum IMT in the right ICA (1.09±0.52 mm vs 1.28±0.77 mm, group differences: −0.19, −0.37 to −0.00) (Figure 1C) compared to the conventional group at 24 months, but showed no difference in the mean IMT in the right ICA between the groups at 24 months. For other atherosclerosis parameters, no difference was found between groups (all P>0.05) (Table 3).
Figure 1.
Male patients. (A) Comparison of mean IMT in the right ICA between the 2 groups at 12 months. (B) Comparison of maximum IMT in the right ICA between the 2 groups at 12 months. (C) Comparison of maximum IMT in the right ICA between the 2 groups at 24 months.
Table 3.
Comparison of atherosclerotic parameters at baseline, 12 months, and 24 months in male participants.
| Variables | Time point | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|---|
| N | 146 | 151 | ||
| Mean IMT in the right CCA, mm | At baseline | 0.82±0.19 | 0.83±0.22 | 0.567 |
| Mean IMT in the left CCA, mm | At baseline | 0.84±0.20 | 0.87±0.26 | 0.272 |
| Mean IMT in the right CCA, mm | 12 months | 0.82±0.19 | 0.84±0.21 | 0.666 |
| Mean IMT in the left CCA, mm | 12 months | 0.85±0.21 | 0.84±0.20 | 0.627 |
| Mean IMT in the right CCA, mm | 24 months | 0.84±0.21 | 0.84±0.24 | 0.881 |
| Mean IMT in the left CCA, mm | 24 months | 0.82±0.18 | 0.86±0.23 | 0.149 |
| Mean IMT in the right bulb, mm | At baseline | 1.08±0.53 | 1.17±0.54 | 0.214 |
| Mean IMT in the left bulb, mm | At baseline | 1.11±0.46 | 1.13±0.48 | 0.667 |
| Mean IMT in the right bulb, mm | 12 months | 1.13±0.52 | 1.20±0.61 | 0.382 |
| Mean IMT in the left bulb, mm | 12 months | 1.19±0.58 | 1.20±0.52 | 0.856 |
| Mean IMT in the right bulb, mm | 24 months | 1.11±0.54 | 1.15±0.56 | 0.607 |
| Mean IMT in the left bulb, mm | 24 months | 1.21±0.66 | 1.15±0.45 | 0.442 |
| Mean IMT in the right ICA, mm | At baseline | 0.87±0.49 | 0.81±0.36 | 0.276 |
| Mean IMT in the left ICA, mm | At baseline | 0.78±0.30 | 0.83±0.42 | 0.259 |
| Mean IMT in the right ICA, mm | 12 months | 0.84±0.41 | 1.02±0.67 | 0.013 |
| Mean IMT in the left ICA, mm | 12 months | 0.86±0.43 | 0.88±0.48 | 0.858 |
| Mean IMT in the right ICA, mm | 24 months | 0.80±0.38 | 0.91±0.57 | 0.107 |
| Mean IMT in the left ICA, mm | 24 months | 0.74±0.35 | 0.79±0.42 | 0.390 |
| Max IMT in the right CCA, mm | At baseline | 1.04±0.25 | 1.08±0.28 | 0.223 |
| Max IMT in the left CCA, mm | At baseline | 1.07±0.28 | 1.13±0.37 | 0.105 |
| Max IMT in the right CCA, mm | 12 months | 1.03±0.26 | 1.07±0.27 | 0.265 |
| Max IMT in the left CCA, mm | 12 months | 1.08±0.28 | 1.06±0.28 | 0.570 |
| Max IMT in the right CCA, mm | 24 months | 1.05±0.27 | 1.07±0.29 | 0.577 |
| Max IMT in the left CCA, mm | 24 months | 1.06±0.25 | 1.09±0.32 | 0.440 |
| Max IMT in the right bulb, mm | At baseline | 1.53±0.73 | 1.63±0.77 | 0.296 |
| Max IMT in the left bulb, mm | At baseline | 1.59±0.69 | 1.66±0.78 | 0.450 |
| Max IMT in the right bulb, mm | 12 months | 1.56±0.72 | 1.64±0.81 | 0.459 |
| Max IMT in the left bulb, mm | 12 months | 1.63±0.80 | 1.63±0.70 | 0.976 |
| Max IMT in the right bulb, mm | 24 months | 1.60±0.73 | 1.61±0.77 | 0.927 |
| Max IMT in the left bulb, mm | 24 months | 1.71±0.84 | 1.66±0.63 | 0.568 |
| Max IMT in the right ICA, mm | At baseline | 1.16±0.60 | 1.11±0.53 | 0.523 |
| Max IMT in the left ICA, mm | At baseline | 1.05±0.41 | 1.12±0.58 | 0.259 |
| Max IMT in the right ICA, mm | 12 months | 1.14±0.59 | 1.39±0.88 | 0.016 |
| Max IMT in the left ICA, mm | 12 months | 1.18±0.61 | 1.23±0.74 | 0.602 |
| Max IMT in the right ICA, mm | 24 months | 1.09±0.52 | 1.28±0.77 | 0.049 |
| Max IMT in the left ICA, mm | 24 months | 1.01±0.45 | 1.10±0.57 | 0.221 |
| Plaque area, mm2 | At baseline | 11.46±6.14 | 12.85±10.59 | 0.294 |
| Plaque gray scale median | At baseline | 49.94±18.95 | 52.75±23.45 | 0.379 |
| Plaque area, mm2 | 12 months | 12.72±6.00 | 12.67±5.41 | 0.968 |
| Plaque area, mm2 | 24 months | 12.68±6.45 | 11.32±5.52 | 0.189 |
| Plaque gray scale median | 12 months | 59.45±31.73 | 52.18±18.87 | 0.312 |
| Plaque gray scale median | 24 months | 52.15±27.56 | 53.26±19.64 | 0.287 |
Comparison of Atherosclerotic Parameters in Female Participants at 12 Months and 24 Months
For female patients, our results also showed that sitagliptin significantly reduced the mean IMT (1.01±0.47 mm vs 1.23±0.51 mm, P=0.049) and the maximum IMT (1.39±0.65 mm vs 1.71±0.77 mm, P=0.042) in the right bulb compared to the conventional group at 12 months (Figure 2). However, the difference between these 2 indexes was not significant at 24 months. Similarly, no significant difference was noted for other atherosclerosis indicators (all P>0.05) (Table 4).
Figure 2.
Female patients. (A) Comparison of mean IMT in the right bulb between the 2 groups at 12 months. Figure (B) Comparison of maximum IMT in the right bulb between the 2 groups at 12 months.
Table 4.
Comparison of atherosclerotic parameters at baseline, 12 months, and 24 months in female participants.
| Variables | Time point | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|---|
| N | 76 | 69 | ||
| Mean IMT in the right CCA, mm | At baseline | 0.83±0.16 | 0.79±0.15 | 0.115 |
| Mean IMT in the left CCA, mm | At baseline | 0.83±0.20 | 0.81±0.21 | 0.624 |
| Mean IMT in the right CCA, mm | 12 months | 0.81±0.17 | 0.79±0.15 | 0.624 |
| Mean IMT in the left CCA, mm | 12 months | 0.80±0.15 | 0.82±0.16 | 0.549 |
| Mean IMT in the right CCA, mm | 24 months | 0.82±0.19 | 0.81±0.18 | 0.748 |
| Mean IMT in the left CCA, mm | 24 months | 0.81±0.17 | 0.82±0.20 | 0.954 |
| Mean IMT in the right bulb, mm | At baseline | 1.14±0.66 | 1.09±0.41 | 0.621 |
| Mean IMT in the left bulb, mm | At baseline | 1.13±0.53 | 1.04±0.49 | 0.340 |
| Mean IMT in the right bulb, mm | 12 months | 1.01±0.47 | 1.23±0.51 | 0.049 |
| Mean IMT in the left bulb, mm | 12 months | 1.24±0.75 | 1.19±0.59 | 0.750 |
| Mean IMT in the right bulb, mm | 24 months | 1.14±0.61 | 1.17±0.48 | 0.776 |
| Mean IMT in the left bulb, mm | 24 months | 1.16±0.64 | 1.24±0.72 | 0.592 |
| Mean IMT in the right ICA, mm | At baseline | 0.69±0.28 | 0.73±0.30 | 0.459 |
| Mean IMT in the left ICA, mm | At baseline | 0.69±0.18 | 0.75±0.42 | 0.367 |
| Mean IMT in the right ICA, mm | 12 months | 0.80±0.35 | 0.83±0.49 | 0.797 |
| Mean IMT in the left ICA, mm | 12 months | 0.90±0.46 | 0.83±0.42 | 0.497 |
| Mean IMT in the right ICA, mm | 24 months | 0.70±0.30 | 0.80±0.57 | 0.323 |
| Mean IMT in the left ICA, mm | 24 months | 0.69±0.29 | 0.80±0.42 | 0.169 |
| Max IMT in the right CCA, mm | At baseline | 1.06±0.21 | 1.01±0.20 | 0.129 |
| Max IMT in the left CCA, mm | At baseline | 1.05±0.35 | 1.04±0.26 | 0.806 |
| Max IMT in the right CCA, mm | 12 months | 1.01±0.22 | 1.00±0.22 | 0.811 |
| Max IMT in the left CCA, mm | 12 months | 1.02±0.24 | 1.03±0.22 | 0.926 |
| Max IMT in the right CCA, mm | 24 months | 1.06±0.29 | 1.02±0.23 | 0.524 |
| Max IMT in the left CCA, mm | 24 months | 1.04±0.25 | 1.04±0.27 | 0.989 |
| Max IMT in the right bulb, mm | At baseline | 1.62±1.01 | 1.60±0.65 | 0.864 |
| Max IMT in the left bulb, mm | At baseline | 1.62±0.80 | 1.49±0.80 | 0.367 |
| Max IMT in the right bulb, mm | 12 months | 1.39±0.65 | 1.71±0.77 | 0.042 |
| Max IMT in the left bulb, mm | 12 months | 1.61±0.94 | 1.66±0.83 | 0.802 |
| Max IMT in the right bulb, mm | 24 months | 1.63±0.88 | 1.71±0.70 | 0.628 |
| Max IMT in the left bulb, mm | 24 months | 1.59±0.81 | 1.71±0.96 | 0.515 |
| Max IMT in the right ICA, mm | At baseline | 0.93±0.40 | 1.00±0.44 | 0.374 |
| Max IMT in the left ICA, mm | At baseline | 0.92±0.28 | 0.98±0.53 | 0.485 |
| Max IMT in the right ICA, mm | 12 months | 1.05±0.44 | 1.10±0.58 | 0.685 |
| Max IMT in the left ICA, mm | 12 months | 1.20±0.59 | 1.09±0.50 | 0.357 |
| Max IMT in the right ICA, mm | 24 months | 0.94±0.35 | 1.06±0.72 | 0.328 |
| Max IMT in the left ICA, mm | 24 months | 0.97±0.49 | 1.08±0.57 | 0.360 |
| Plaque area, mm2 | At baseline | 11.17±9.44 | 9.24±4.31 | 0.212 |
| Plaque gray scale median | At baseline | 52.79±28.26 | 51.81±17.33 | 0.842 |
| Plaque area, mm2 | 12 months | 12.66±9.34 | 11.73±4.07 | 0.668 |
| Plaque area, mm2 | 24 months | 10.86±6.81 | 10.30±4.05 | 0.668 |
| Plaque gray scale median | 12 months | 54.77±40.66 | 75.57±53.51 | 0.203 |
| Plaque gray scale median | 24 months | 43.92±19.10 | 51.81±19.85 | 0.096 |
Comparison of Blood Lipid, Blood Glucose, and Other Indexes in Male Participants at 24 Months
Our results found that in male patients, sitagliptin did not remarkably reduce the levels of blood lipids and blood glucose in the diabetic patients compared to the control group. Blood lipid and blood glucose-associated indices included high-density lipoprotein cholesterol, triglyceride, small dense low-density lipoprotein cholesterol, remnant-like particle cholesterol, malondialdehyde-modified low-density lipoprotein, HbA1c, and fasting plasma glucose, except for high-molecular-weight adiponectin. Similarly, there were no significant inter-group differences in other indicators, including weight, waist circumference, SBP, DBP, pulse rate, 1,5-anhydroglucitol,1,4-anhydro-D-glucitol, lactic dehydrogenase, AST, ALT, BUN, serum creatinine, eGFR, cystatin C, urinary albumin/creatinine ratio, and uric acid (Table 5).
Table 5.
Comparison of blood lipid, blood glucose, and other indexes in male participants at 24 months.
| Variables | Time point | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|---|
| N | 146 | 151 | ||
| Weight (kg) | 24 months | 68.37±10.59 | 68.46±11.41 | 0.947 |
| Waist circumference (cm) | 24 months | 90.24±10.01 | 90.76±10.77 | 0.737 |
| Systolic blood pressure (mmHg) | 24 months | 130.05±16.23 | 128.87±16.79 | 0.567 |
| Diastolic blood pressure (mmHg) | 24 months | 74.07±11.27 | 72.75±10.19 | 0.323 |
| Pulse rate (bpm) | 24 months | 72.11±12.83 | 70.08±11.07 | 0.188 |
| HbA1c (%) | 24 months | 6.58±0.61 | 6.67±0.63 | 0.260 |
| Fasting plasma glucose (mg/dL) | 24 months | 132.81±38.27 | 130.58±35.52 | 0.640 |
| 1,5-anhydroglucitol,1,4-anhydro-D-glucitol (μg/mL) | 24 months | 16.22±8.79 | 16.34±8.61 | 0.920 |
| High molecular weight adiponectin (μg/mL) | 24 months | 3.59±3.79 | 5.08±4.77 | 0.012 |
| Lactic dehydrogenase (U/L) | 24 months | 195.60±39.23 | 209.07±87.72 | 0.126 |
| High-density lipoprotein cholesterol (mg/dL) | 24 months | 49.59±13.35 | 51.21±14.55 | 0.360 |
| Triglyceride (mg/dL) | 24 months | 151.25±89.20 | 132.45±75.07 | 0.071 |
| Small dense low-density lipoprotein cholesterol (mg/dL) | 24 months | 35.33±17.10 | 37.24±20.62 | 0.462 |
| Remnant-like particle cholesterol (mg/dL) | 24 months | 5.10±3.90 | 5.44±5.03 | 0.586 |
| Malondialdehyde-modified low-density lipoprotein (U/l) | 24 months | 121.44±36.31 | 120.69±41.67 | 0.888 |
| Aspartate aminotransferase (U/l) | 24 months | 26.26±14.40 | 27.42±16.70 | 0.554 |
| Alanine aminotransferase (U/l) | 24 months | 25.08±16.24 | 25.27±16.58 | 0.924 |
| Blood urea nitrogen (mg/dL) | 24 months | 16.90±5.39 | 18.41±6.90 | 0.055 |
| Serum creatinine (mg/dL) | 24 months | 0.98±0.31 | 0.98±0.30 | 0.885 |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 24 months | 63.88±17.55 | 63.65±17.60 | 0.915 |
| Cystatin C (mg/dL) | 24 months | 1.07±0.32 | 1.07±0.34 | 0.954 |
| Urinary albumin/creatinine ratio (mg/gCre) | 24 months | 15.00 (6.15–38.75) | 17.00 (7.90–24.80) | 0.943 |
| Uric acid (μmol/l) | 24 months | 6.07±1.20 | 6.08±1.23 | 0.949 |
Comparison of Blood Lipid, Blood Glucose, and Other Indexes in Female Participants at 24 Months
Our results demonstrated that sitagliptin significantly improved HbA1c levels in female participants compared to the control group (6.52±0.50 vs 6.83±0.82, P=0.010). However, sitagliptin had no impact on blood lipid levels between the groups. Blood lipid-associated indices included high-molecular-weight adiponectin, high-density lipoprotein cholesterol, triglyceride, small dense low-density lipoprotein cholesterol, remnant-like particle cholesterol, and malondialdehyde-modified low-density lipoprotein. Similarly, sitagliptin also had no significant impact on either group for other indicators, including weight, WC, SBP, DBP, pulse rate, FPG, 1,5-anhydroglucitol,1,4-anhydro-D-glucitol, lactic dehydrogenase, AST, ALT, BUN, serum creatinine, eGFR, cystatin C, urinary albumin/creatinine ratio, and uric acid (Table 6).
Table 6.
Comparison of blood lipid, blood glucose, and other indexes in female participants at 24 months.
| Variables | Time point | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|---|
| N | 76 | 69 | ||
| Weight (kg) | 24 months | 57.55±14.19 | 55.71±10.48 | 0.457 |
| Waist circumference (cm) | 24 months | 90.26±12.50 | 86.37±10.48 | 0.163 |
| Systolic blood pressure (mmHg) | 24 months | 129.39±15.27 | 131.53±20.70 | 0.510 |
| Diastolic blood pressure (mmHg) | 24 months | 71.77±12.22 | 70.51±11.97 | 0.560 |
| Pulse rate (bpm) | 24 months | 72.42±11.21 | 72.80±11.05 | 0.857 |
| HbA1c (%) | 24 months | 6.52±0.50 | 6.83±0.82 | 0.010 |
| Fasting plasma glucose (mg/dL) | 24 months | 123.68±29.32 | 128.19±42.40 | 0.505 |
| 1,5-anhydroglucitol,1,4-anhydro-D-glucitol (μg/mL) | 24 months | 16.95±8.80 | 14.52±7.94 | 0.135 |
| High molecular weight adiponectin (μg/mL) | 24 months | 5.40±3.43 | 6.09±5.45 | 0.428 |
| Lactic dehydrogenase (U/L) | 24 months | 202.46±42.14 | 215.97±37.76 | 0.078 |
| High-density lipoprotein cholesterol (mg/dL) | 24 months | 56.67±12.66 | 58.30±15.78 | 0.531 |
| Triglyceride (mg/dL) | 24 months | 114.25±51.09 | 130.89±70.05 | 0.135 |
| Small dense low-density lipoprotein cholesterol (mg/dL) | 24 months | 30.41±16.28 | 35.05±18.98 | 0.174 |
| Remnant-like particle cholesterol (mg/dL) | 24 months | 4.27±2.34 | 4.81±3.04 | 0.305 |
| Malondialdehyde-modified low-density lipoprotein (U/l) | 24 months | 109.10±35.20 | 117.49±38.43 | 0.237 |
| Aspartate aminotransferase (U/l) | 24 months | 22.92±5.78 | 24.73±10.26 | 0.225 |
| Alanine aminotransferase (U/l) | 24 months | 18.53±6.90 | 21.68±14.37 | 0.117 |
| Blood urea nitrogen (mg/dL) | 24 months | 17.79±5.54 | 18.06±8.04 | 0.826 |
| Serum creatinine (mg/dL) | 24 months | 0.72±0.22 | 0.71±0.21 | 0.720 |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 24 months | 65.53±18.99 | 67.02±20.38 | 0.675 |
| Cystatin C (mg/L) | 24 months | 1.09±0.30 | 0.98±0.23 | 0.120 |
| Urinary albumin/creatinine ratio (mg/gCre) | 24 months | 18.05(11.03–29.60) | 18.10 (10.68–92.13) | 0.441 |
| Uric acid (μmol/l) | 24 months | 5.28±1.49 | 5.11±1.69 | 0.577 |
Discussion
To the best of our knowledge, our study is the first to analyze a randomized controlled trial to investigate sex-related differences in sitagliptin treatment in carotid atherosclerosis in T2DM patients based on the PROLOGUE trial [19]. The main results of this study are as follows: (1) for male patients, sitagliptin slows the progression of right carotid IMT in male patients at both 12 and 24 months. However, this effect of sitagliptin appears to be pronounced only in the right ICA, but this influence was not found in other vessels. In terms of blood glucose and blood lipids, sitagliptin only reduced the level of HMWA and had no significant effect on HDL-cholesterol or HbA1c or FPG. (2) For female patients, sitagliptin could also significantly delay the progression of atherosclerosis, but the effect only occurred at 12 months and did not last until 24 months. This effect seemed to be significant only on the right side of the bulb, but this difference was remarkable in other blood vessels. In addition, our results also show that sitagliptin significantly reduced HbA1c levels at 24 months but had no significant effect on blood lipids and renal function.
In clinical practice, IMT of the carotid artery is often measured by ultrasonic examination [26,27], which then allows clinicians to predict and estimate the risk of cardiovascular events and stroke and to develop treatment strategies. Previous studies have shown a positive correlation between carotid artery IMT and cardiovascular events [28,29], irrespective of whether the patients have cardiovascular disease or not. In addition, ultrasonic examination is non-invasive, making it a safe measure to assess cardiovascular events and stroke. For these reasons, the American Heart Association assesses cardiovascular risk by measuring carotid artery IMT, which is an important indicator of cardiovascular risk [30]. The PROLOGUE study [19] measured carotid artery IMT 3 times, and measured multiple arteries, providing enough samples to show statistically significant differences between the groups. Therefore, we had valid reasons to use carotid artery IMT as the primary endpoint in this study.
Previous studies have demonstrated that the use of DPP-4 inhibitors in diabetes patients could significantly reduce the degree of atherosclerosis [23–25] and better control the level of blood glucose [31]. In addition, some clinical trials [32,33] supported the finding that DPP-4 inhibitors have beneficial effects on endothelial function in diabetes patients. However, no prior study looked at the impact of sex-related differences on sitagliptin’s effect on atherosclerosis in T2DM patients. In the present study, we compared the effect of sitagliptin on atherosclerosis between male and female diabetes patients. The results showed that sitagliptin delayed the progression of atherosclerosis in male patients, with benefits significant at both 12 and 24 months. On the other hand, in female patients, sitagliptin delayed the progression of atherosclerosis, but with benefits only significant at 12 months. The PROLOGUE study [19] found no evidence to support the effectiveness of sitagliptin in delaying atherosclerosis in diabetic patients. However, it should be emphasized that in the PROLOGUE study, the authors did not stratify the study groups based on sex; therefore, the results reflected the effectiveness of sitagliptin in all patients overall. In addition, the PROLOGUE study did not distinguish between changes in left and right carotid atherosclerosis. This may potentially explain the discrepancies between the results from the PROLOGUE study and our study. Our findings suggest that sitagliptin only significantly benefits the right ICA in male patients and right bulb in female patients. One unanticipated finding was that sitagliptin had different effects on different carotid arteries, which is different from previous studies. In a cohort study [34] of 1414 participants, the authors compared the left and right carotid atherosclerotic plaques and assessed the degree of carotid atherosclerosis using magnetic resonance imaging (MRI). The results showed that the size and composition of the left and the right carotid atherosclerotic plaques were asymmetrically distributed. Left carotid plaque is prone to intra-plaque bleeding (9.1% vs 5.9%), while right carotid plaque is more prone to calcification (37.4% vs 31.6%). Similarly, Katranas et al [35] also found that the left and the right coronary arteries have significant differences in hemorheology and geometric parameters. Therefore, we speculate that differences in anatomical structures or hemodynamics may also lead to different effects of sitagliptin on different carotid atheroscleroses. Presently, there is no study directly clarifying the difference in carotid artery IMT between males and females treated with sitagliptin. The possible mechanism is that the secretion of estrogen and progesterone in postmenopausal women decreases, thus offsetting the benefits of sitagliptin treatment, but this phenomenon does not exist in men. However, more research is needed to further clarify this hypothesis.
Our study also found that there are sex-specific differences in the effects of sitagliptin on blood glucose and blood lipids. Sitagliptin reduced the level of high-molecular-weight adiponectin in male patients, while it could only reduce HbA1c levels in female patients. No significant differences were observed in weight control, waist circumference, and renal function protection in males or females, which is contrary to the previous results. In a retrospective cohort study [36] of 220 patients with type 2 diabetes, the authors found that weight and HbA1c level decreased significantly after 6 months of sitagliptin treatment. Similarly, Kawasaki et al [37] investigated whether sitagliptin could improve renal function in diabetic patients, and found that the glomerular filtration rate (β=0.20, P=0.024) and blood pressure (β=0.21, P=0.016) were significantly improved after 3 months of sitagliptin treatment. Possible explanations are as follows: (1) the sample size of the PROLOGUE study is relatively larger than that of other studies, providing higher statistical power; (2) the follow-up time of the PROLOGUE study was longer than that of other studies, which produces higher reliability; and (3) the PROLOGUE study was a multicenter randomized controlled trial, suggesting its wide applicability among populations.
Our study has several advantages. First, we explored sex-related differences in sitagliptin treatment in T2DM patients for the first time, and showed that the effect of sitagliptin on atherosclerosis in male T2DM patients is higher than that in female T2DM patients, which suggests that sex-related differences are cause different therapeutic effects. Second, we used the parameters of multiple carotid arteries as the primary endpoint and found that sitagliptin had different effects on different carotid arteries, which suggests that the appropriate outcome should be selected in clinical research to reduce selection bias. This study also has some shortcomings. First, the research object of this study was a Japanese population. Therefore, whether the conclusions are applicable to other populations still needs to be assessed. Second, based on the current data, we cannot explore the mechanism of sitagliptin only acting on some carotid arteries, nor can we accurately analyze the reasons for the decrease of HbA1c level without significant difference in the degree of atherosclerosis. Third, information on other drugs (eg, antidiabetic drugs, insulin, statin) in the ROLOGUE study is lacking and may potentially affect final conclusions. Fourth, we found a significant difference in age between males and females (68.44±9.22 vs 71.19±8.94, P=0.003). However, it is important to note that the difference in age between male and female was only 2.7 years. Although there was a significant difference in age between males and females, this small difference might not lead to substantial changes in clinical practice. Fifth, we found that sitagliptin significantly improved HbA1c levels in female patients after 24 months, but this phenomenon was not observed in male patients. The possible reason is speculated to be related to the severity of diabetes and the underlying diseases since the participants included in the PROLOGUE Trial basically did not have any diabetes-related diseases and had too many underlying diseases. However, more studies are needed to verify this conclusion.
Conclusions
Our results suggest that sitagliptin slows the progression of right carotid IMT in male patients. However, more studies are needed to confirm this conclusion in female patients.
Acknowledgements
We thank the participants and the staff who participated in the PROLOGUE study.
Abbreviations
- T2DM
type 2 diabetes mellitus
- IMT
intima-media thickness
- ICA
internal carotid arteries
- CHD
coronary heart disease
- IS
ischemic stroke
- DPP-4
Dipeptidyl peptidase-4
- GLP-1
glucagon-like peptide-1
- GIP
gastric inhibitory polypeptide
- RCT
randomized controlled trial
- HbA1c
glycosylated hemoglobin
- CCA
common carotid arteries
- OR
odds ratio
- CI
confidence interval
- WC
waist circumference
- SDP
systolic blood pressure
- DBP
diastolic blood pressure
- PR
pulse rate
- FPG
fasting plasma glucose
- HMWA
high-molecular-weight adiponectin
- LD
lactic dehydrogenase
- HDL-cholesterol
high-density lipoprotein cholesterol
- TG
triglyceride
- TG
triglyceride
- small DLD-cholesterol
small dense low-density lipoprotein cholesterol
- RLP-cholesterol
remnant-like particle cholesterol
- MMDLI
malondialdehyde-modified low-density lipoprotein
- AST
aspartate aminotransferase
- ALT
alanine aminotransferase
- BUN
blood urea nitrogen
- eGFR
estimated glomerular filtration rate
Footnotes
Conflict of interest: None declared
Declaration of Figures’ Authenticity
All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.
Trial registration: UMIN000004490
Financial support: This work was supported by Guangxi Zhuang Autonomous Region Health Department Self-Raised Research Fund Project (No. Z20201056) and Guangxi Medical and Health Appropriate Technology Development, Promotion and Application Funding Project (No. S2020007)
References
- 1.Wang J, Sun C, Gerdes N, et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med. 2015;21(7):820–26. doi: 10.1038/nm.3890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166–72. doi: 10.1038/nm.3258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Liebeskind DS, Cotsonis GA, Saver JL, et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Investigators. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. Ann Neurol. 2011;69(6):963–74. doi: 10.1002/ana.22354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dadu RT, Fornage M, Virani SS, et al. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013;44(7):1803–8. doi: 10.1161/STROKEAHA.113.001128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ogagarue ER, Lutsey PL, Klein R, et al. Association of ideal cardiovascular health metrics and retinal microvascular findings: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2013;2(6):e000430. doi: 10.1161/JAHA.113.000430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Muscogiuri G, Annweiler C, Duval G, et al. Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. Int J Cardiol. 2017;230:577–84. doi: 10.1016/j.ijcard.2016.12.053. [DOI] [PubMed] [Google Scholar]
- 7.Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018;271:177–81. doi: 10.1016/j.atherosclerosis.2018.02.004. [DOI] [PubMed] [Google Scholar]
- 8.Lv P, Jin H, Liu Y, et al. Comparison of risk factor between lacunar stroke and large artery atherosclerosis stroke: A cross-sectional study in China. PLoS One. 2016;11(3):e0149605. doi: 10.1371/journal.pone.0149605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yin JH, Song ZY, Shan PF, et al. Age- and gender-specific prevalence of carotid atherosclerosis and its association with metabolic syndrome in Hangzhou, China. Clin Endocrinol (Oxf) 2012;76(6):802–9. doi: 10.1111/j.1365-2265.2011.04198.x. [DOI] [PubMed] [Google Scholar]
- 10.Amer MS, Khater MS, Omar OH, et al. Association between Framingham risk score and subclinical atherosclerosis among elderly with both type 2 diabetes mellitus and healthy subjects. Am J Cardiovasc Dis. 2014;4(1):14–19. [PMC free article] [PubMed] [Google Scholar]
- 11.Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37(2):191–204. doi: 10.1161/ATVBAHA.116.306256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nozue T, Yamamoto S, Tohyama S, et al. TRUTH Investigators. Impact of diabetes mellitus on coronary atherosclerosis and plaque composition under statin therapy – subanalysis of the TRUTH study. Circ J. 2012;76(9):2188–96. doi: 10.1253/circj.cj-11-1303. [DOI] [PubMed] [Google Scholar]
- 13.Svensson AK, Svensson T, Kitlinski M, et al. Incident diabetes mellitus may explain the association between sleep duration and incident coronary heart disease. Diabetologia. 2018;61(2):331–41. doi: 10.1007/s00125-017-4464-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Doi Y, Ninomiya T, Hata J, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: The Hisayama study. Stroke. 2010;41(2):203–9. doi: 10.1161/STROKEAHA.109.564708. [DOI] [PubMed] [Google Scholar]
- 15.Overbeek JA, Bakker M, van der Heijden AAWA, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004. doi: 10.1002/dmrr.3004. [DOI] [PubMed] [Google Scholar]
- 16.Patel BD, Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014;74:574–605. doi: 10.1016/j.ejmech.2013.12.038. [DOI] [PubMed] [Google Scholar]
- 17.Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59(3):265–76. doi: 10.1016/j.jacc.2011.07.053. [DOI] [PubMed] [Google Scholar]
- 18.Zeng Y, Li C, Guan M, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol. 2014;13:32. doi: 10.1186/1475-2840-13-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Oyama J, Murohara T, Kitakaze M, et al. PROLOGUE Study Investigators. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: The PROLOGUE randomized controlled trial. PLoS Med. 2016;13(6):e1002051. doi: 10.1371/journal.pmed.1002051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Nozue T, Fukui K, Koyama Y, et al. TRUST Investigators. Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study. Am J Cardiovasc Dis. 2016;6(4):153–62. [PMC free article] [PubMed] [Google Scholar]
- 21.Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. doi: 10.1056/NEJMoa1501352. [Erratum in: N Engl J Med. 2015;373(6):586] [DOI] [PubMed] [Google Scholar]
- 22.McGuire DK, Van de Werf F, Armstrong PW, et al. Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: Secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(2):126–35. doi: 10.1001/jamacardio.2016.0103. [DOI] [PubMed] [Google Scholar]
- 23.Katakami N, Mita T, Irie Y, et al. Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) Collaborators. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: A post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE) Cardiovasc Diabetol. 2018;17(1):24. doi: 10.1186/s12933-018-0666-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Fan M, Li Y, Zhang S. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95(2):e2386. doi: 10.1097/MD.0000000000002386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Oyama J, Ishizu T, Sato Y, Kodama K, et al. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. Int J Cardiol. 2014;174(2):383–84. doi: 10.1016/j.ijcard.2014.03.204. [DOI] [PubMed] [Google Scholar]
- 26.Plasencia Martínez JM, Garcia Santos JM, Paredes Martinez ML, Pastor AM. Carotid intima-media thickness and hemodynamic parameters: Reproducibility of manual measurements with Doppler ultrasound. Med Ultrason. 2015;17(2):167–74. doi: 10.11152/mu.2013.2066.172.ci-m. [DOI] [PubMed] [Google Scholar]
- 27.Giannarelli C, Bianchini E, Bruno RM, et al. Local carotid stiffness and intima-media thickness assessment by a novel ultrasound-based system in essential hypertension. Atherosclerosis. 2012;223(2):372–77. doi: 10.1016/j.atherosclerosis.2012.05.027. [DOI] [PubMed] [Google Scholar]
- 28.Jung JM, Kwon DY, Han C, et al. Increased carotid intima-media thickness and plasma homocysteine levels predict cardiovascular and all-cause death: A population-based cohort study. Eur Neurol. 2013;70(1–2):1–5. doi: 10.1159/000343807. [DOI] [PubMed] [Google Scholar]
- 29.Zhang Y, Fang X, Hua Y, et al. Carotid artery plaques, carotid intima-media thickness, and risk of cardiovascular events and all-cause death in older adults: A 5-year prospective, community-based study. Angiology. 2018;69(2):120–29. doi: 10.1177/0003319717716842. [DOI] [PubMed] [Google Scholar]
- 30.Greenland P, Alpert JS, Beller GA, et al. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103. doi: 10.1016/j.jacc.2010.09.001. [DOI] [PubMed] [Google Scholar]
- 31.Shimoda S, Iwashita S, Ichimori S, et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J. 2013;60(10):1207–14. doi: 10.1507/endocrj.ej13-0198. [DOI] [PubMed] [Google Scholar]
- 32.Maruhashi T, Higashi Y, Kihara Y, et al. PROLOGUE Study Investigators. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: A sub-analysis of the PROLOGUE study. Cardiovasc Diabetol. 2016;15(1):134. doi: 10.1186/s12933-016-0438-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–70. doi: 10.3346/jkms.2012.27.11.1364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Selwaness M, van den Bouwhuijsen Q, van Onkelen RS, et al. Atherosclerotic plaque in the left carotid artery is more vulnerable than in the right. Stroke. 2014;45(11):3226–30. doi: 10.1161/STROKEAHA.114.005202. [DOI] [PubMed] [Google Scholar]
- 35.Katranas SA, Kelekis AL, Antoniadis AP, et al. Differences in stress forces and geometry between left and right coronary artery: A pathophysiological aspect of atherosclerosis heterogeneity. Hellenic J Cardiol. 2015;56(3):217–23. [PubMed] [Google Scholar]
- 36.Yanai H, Adachi H, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: A chart-based analysis. J Clin Med Res. 2012;4(4):251–58. doi: 10.4021/jocmr975w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Kawasaki I, Hiura Y, Tamai A, et al. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes. 2015;7(1):41–46. doi: 10.1111/1753-0407.12153. [DOI] [PubMed] [Google Scholar]